26/02/2025

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

26/02/2025

Feb 26, 2025, 15:38 | Career
UICC is looking for a Social Media and Content Specialist
UICC shared a post on LinkedIn: “We’re hiring! UICC is looking for a Social Media…
Feb 26, 2025, 15:34 | Blog
Sarah Louden: University of Kansas Breast Cancer Year in Review
Sarah Louden, CEO and Founder of Total Health Oncology, shared a post on LinkedIn: "University…
Feb 26, 2025, 15:33 | Stories
Voice of the families: Ayman Kelifa and his father - CANCaRe Africa
CANCaRe Africa shared a post on LinkedIn: "Voice of the families, post 28 Ayman Kelifa…
Feb 26, 2025, 15:22 | Career
Kenji López-Cuevas: I have started in a new position at UICC
Kenji López-Cuevas, Treasurer and Chairperson of the Finance, Risk and Audit Committee at UICC, shared…
Feb 26, 2025, 15:16 | Blog
Miriam Mutebi: Where you live, should not determine if you live
Miriam Mutebi, Assistant Professor in the Department of Surgery at the Aga Khan University Hospital,…
Feb 26, 2025, 15:12 | Blog
The powerful synergy between MiNK’s allo-iNKT cells and chemotherapy in Gastric Cancer - MiNK Therapeutics
MiNK Therapeutics shared a post on LinkedIn: "Yesterday at AACRIO25, we presented new translational insights…
Feb 26, 2025, 15:07 | Opinion
Debunking Cancer Prevention: The Essential Role of Risk Reduction - Sami Mansfield
"Every February, we emphasize National Cancer Prevention Month - a time devoted to raising awareness…
Feb 26, 2025, 13:39 | Career
Dan Theodorescu has been appointed as the Director of University of Arizona Cancer Center
On February 21, 2025, the University of Arizona Health Sciences named Dan Theodorescu, MD, PhD,…
Feb 26, 2025, 13:37 | Science
Olivier Elemento: How do early lung tumors evolve?
Olivier Elemento, Director of Englander Institute for Precision Medicine, shared an article by Junbum Kim,…
Feb 26, 2025, 13:29 | Drugs
FDA approves Vimseltinib(Romvimza) for symptomatic Tenosynovial Giant Cell Tumor (TGCT)
On February 14, 2025, the U.S. Food and Drug Administration (FDA) approved Vimseltinib (Romvimza) for…
All: 77 Posts: 11 - 20
Special Coverage